Xinhé Bio's AI-Driven mRNA Personalized Neoantigen Vaccine XH001 Granted IND Approval for Clinical Trials

Approval Information for XH001 Injection IND

Postoperative tumor recurrence is the biggest clinical pain point, with limited traditional treatment options.

Currently, with the popularization of physical examinations, an increasing number of tumors are being detected at an early stage. Many patients have gained the opportunity for surgical treatment; however, even after receiving various perioperative adjuvant therapies, postoperative recurrence and metastasis remain critical issues that need to be addressed in clinical practice. Once a tumor recurs, it is often difficult to perform radical treatment, which means that patients..."Healthy" status turned into advanced tumor patients. Clinically, there is an urgent need for an advanced treatment method that can effectively reduce the risk of tumor recurrence to improve overall treatment outcomes and patient survival rates. However, the biological characteristics of tumors vary significantly among different patients. Traditional one-size-fits-all treatments always result in some patients benefiting while others show no response, making it difficult to achieve precise personalized intervention.。

NeoCura's self-developedThe entry of NeoCura's mRNA personalized tumor neoantigen vaccine XH001 into clinical research means that treatment can be "customized" based on the patient's tumor mutation profile, truly achieving the revolutionary concept of "one person, one drug" in personalized therapy. This is a prime example of "precision medicine." The clinical approval of XH001 brings hope for solving the challenge of recurrence after potentially curative cancer treatments.

XH001 Empowers Precision Targeting with AI and Disrupts Previous Pain Points with mRNA Vaccine Technology.

XH001 is the first personalized tumor neoantigen vaccine developed by NeoCura based on its AI-driven mRNA technology platform. By utilizing the self-developed and proprietary NeoCura AI ALPINE system to screen for highly immunogenic neoantigens, the vaccine integrates the unique mutation profile of the patient’s tumor cells with HLA typing data to customize a corresponding personalized neoantigen vaccine. This activates tumor-specific T cells, precisely eliminating residual tumor cells and reducing the risk of recurrence at the source.

In addition, compared with traditional drugs, another significant advantage of XH001 is that traditional postoperative adjuvant treatments are usually dominated by chemotherapy drugs, which inevitably have toxic side effects and thus are difficult to be used over the long term. However, the immune memory established by vaccines in the human body can last for a long time, providing patients with prolonged protection that extends beyond the period of drug administration.

NeoCura, with its full-chain independent R&D capabilities, has built industry-leadingmRNA Technology Ecosystem. XH001, developed on this basis with the AI-driven NeoCura ALPINE system, has achieved a breakthrough lead in the global tumor immunotherapy field.

According to the introduction, the R&D of XH001 innovatively utilized the five major scientific platforms independently built by NeoCura. These platforms delve into various aspects such as neoantigen prediction, presentation, immunogenicity validation, mRNA design and efficient delivery, as well as mRNA drug manufacturing processes, comprehensively enhancing the efficiency of vaccine development and therapeutic effects. Relevant data shows that the vaccine is well-tolerated and significantly outperforms similar overseas products in key performance indicators such as tumor-specific T-cell activation and maintenance. Clinical research initiated by investigators (IIT) indicates that XH001 demonstrates good safety and tolerability while effectively activating specific T-cell immune responses in the body, laying a solid foundation for Phase I clinical trials.

As one of the earlier layouts in ChinaAs one of the companies researching and developing mRNA innovative drugs, NeoCura has always been at the forefront of the tumor immunotherapy field, continuously exploring the boundaries of innovation as a pioneer.This clinical approval marks a key breakthrough in the clinical transformation of NeoCura in the mRNA innovative drug field, continuously expanding its leading advantage in the industry.According to the clinical trial plan, NeoCura will collaborate with multiple Class III, Grade A hospitals in China to conduct a Phase I clinical trial of XH001 injection for adjuvant treatment in patients with high-risk recurrent solid tumors post-radical surgery. The trial will systematically evaluate its safety, tolerability, and preliminary efficacy, providing critical data support for subsequent clinical development.

The approval of XH001 marks China's entry into the first tier in the global race for tumor immunotherapy. We look forward to mRNA neoantigen vaccines bringing long-term survival benefits to patients as clinical trials progress, leading the tumor treatment industry into a new era with better efficacy and greater accessibility.

NeoCura is a high-tech enterprise that relies on AI technology to focus on the research and development of innovative RNA drugs. It has built a multi-omics big data collection platform and a multi-layer bioinformatics database, using AI and bioinformatics technologies for in-depth drug target mining and fully automated drug design for innovative RNA drug research. It has established a leading RNA drug production center in China to support pipeline research and clinical needs.